Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy [View all]
Millions of women with breast cancer could be spared chemotherapy with a groundbreaking genomic test, according to the results of a trial that could transform healthcare guidelines worldwide.
Treatment for breast cancer, the worlds most prevalent form of the disease, involves surgery to remove tumours. Chemotherapy is then usually recommended when doctors believe there is a risk the disease will return.
But chemotherapys toxic side-effects, which can include hair loss, rashes, nausea, insomnia and fatigue, are physically and emotionally gruelling for patients. Some women may face life-changing consequences such as infertility, cognitive impairment or early menopause.
For decades, there has been little choice for patients. Now scientists have developed a genomic test that can spot who needs chemotherapy and who doesnt. The breakthrough enables doctors to determine which patients can safely skip it, paving the way for a new era of personalised medicine.
https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy